Heart failure (HF) represents the final common pathway of virtually every form of structural heart disease, affecting at least 26 million people worldwide and carrying a five-year mortality that rivals many malignancies.1 For the clinician, HF is not a single disease but a clinical syndrome defined by symptoms and signs resulting from structural or functional cardiac abnormality, characterized by reduced cardiac output and/or elevated intracardiac pressures at rest or with stress.2 Understanding the pathophysiological mechanisms that drive disease progression is not merely academic: each mechanism represents a therapeutic target, and the drugs that have transformed HF outcomes over the past three decades were developed precisely by interrupting these pathways. This module establishes the mechanistic framework upon which all subsequent CHF pharmacology modules are built.
The 2022 AHA/ACC/HFSA Heart Failure Guidelines and the 2021 ESC Guidelines classify heart failure by left ventricular ejection fraction (LVEF) because this single measurement most reliably stratifies prognosis, guides therapy, and defines the evidence base for pharmacological intervention.2·3
HFrEF is defined as HF with an LVEF ≤40%. This is the phenotype for which the largest and most robust evidence base exists, and it is the dominant focus of guideline-directed medical therapy (GDMT). The underlying pathology is typically dilated cardiomyopathy, ischemic or non-ischemic, in which myocyte loss, fibrosis, and pathological remodeling reduce systolic contractile performance. The cardinal hemodynamic features are reduced stroke volume, compensatory ventricular dilation, elevated filling pressures, and, as the syndrome advances, reduced cardiac output at rest.2
HFpEF is defined as HF with an LVEF ≥50%, with symptoms and signs of HF, and objective evidence of elevated cardiac filling pressures (at rest or with exercise), in the absence of alternative diagnoses.2 HFpEF now accounts for at least half of all HF hospitalizations, and its prevalence is rising in parallel with aging, obesity, hypertension, and diabetes.4 The pathophysiology centers on impaired myocardial relaxation (diastolic dysfunction), reduced left ventricular compliance, and a systemic pro-inflammatory state driven by comorbidities, rather than primary systolic failure. For decades, no therapy convincingly reduced mortality in HFpEF; sodium-glucose cotransporter 2 (SGLT2) inhibitors have now emerged as the first class to demonstrate meaningful benefit in this population (addressed in CHF-05).4
HFmrEF encompasses LVEF 41–49% and represents a heterogeneous transition zone.3 Some patients in this group have recovering HFrEF (post-myocarditis, post-partum, alcohol-related), while others represent early HFpEF. Post-hoc and meta-analytic data suggest that renin-angiotensin-aldosterone system (RAAS) blockers and beta-blockers confer benefit in HFmrEF, and current guidelines recommend their use in this group based on extrapolation from HFrEF trials.2·3
Classifying the patient's hemodynamic profile at presentation guides immediate management decisions. The Stevenson hemodynamic classification uses two axes: perfusion (warm vs. cold) and congestion (wet vs. dry).5 Most acute decompensated HF presentations are "warm and wet" (adequate perfusion, fluid overloaded); these patients respond to decongestion. Patients who are "cold and wet" (low perfusion, fluid overloaded) require careful diuresis combined with hemodynamic support. The "cold and dry" profile (low perfusion without congestion) represents advanced disease and may require inotropic support or mechanical circulatory assistance. Understanding this framework is essential for rational pharmacological decision-making in the acute setting.5
The modern understanding of HF pathophysiology was transformed by the recognition that compensatory neurohormonal responses, initially adaptive, become the primary drivers of myocardial injury and progressive dysfunction when chronically activated. This insight, developed across the 1980s and 1990s, established neurohormonal blockade as the cornerstone of HF therapy.6
In HF, reduced renal perfusion pressure activates the juxtaglomerular apparatus to release renin, which cleaves angiotensinogen to angiotensin I (Ang I). Angiotensin-converting enzyme (ACE) converts Ang I to angiotensin II (Ang II), the primary effector of the RAAS. In the short term, Ang II supports perfusion through arterial vasoconstriction, sodium retention, and aldosterone release.7 However, with sustained HF, chronically elevated Ang II drives maladaptive responses: (1) pathological afterload elevation that increases myocardial wall stress; (2) direct cardiomyocyte hypertrophy and fibroblast activation leading to myocardial fibrosis; (3) promotion of cardiac apoptosis; and (4) neurohormonal amplification through sympathetic activation and vasopressin release.7 Aldosterone, released downstream of Ang II, further promotes sodium retention, potassium wasting, and myocardial and vascular fibrosis through mineralocorticoid receptor activation. These fibrotic effects are independent of its hemodynamic actions and persist even when sodium levels are normal.8 The RAAS is not confined to the circulation. Tissue (cardiac and renal) RAAS components, including locally synthesized Ang II and aldosterone, contribute substantially to the maladaptive remodeling process and are not fully suppressed by conventional circulating-RAAS blockade.7 This observation is part of the rationale for combining ACE inhibitors or ARBs with mineralocorticoid receptor antagonists in GDMT.
Reduced cardiac output in HF reflexively activates the sympathetic nervous system, initially restoring heart rate and contractility through beta-1 adrenergic receptor stimulation, and augmenting vascular resistance through alpha-1-mediated vasoconstriction.6 These responses are life-sustaining in acute, reversible conditions. In chronic HF, however, sustained catecholamine excess causes: (1) progressive cardiomyocyte toxicity through calcium overload and mitochondrial dysfunction; (2) beta-1 adrenergic receptor downregulation and uncoupling, reducing the myocardium's intrinsic inotropic reserve; (3) proarrhythmic effects through increased automaticity and afterdepolarizations; and (4) further RAAS activation through beta-1-mediated renin release.6 Plasma norepinephrine levels in HF correlate directly with mortality: a landmark observation by Cohn et al. that first established the SNS as a therapeutic target.9
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released in response to elevated myocardial wall stress. These peptides act as endogenous counter-regulators to the RAAS and SNS: promoting natriuresis and diuresis, inducing vasodilation, inhibiting RAAS and SNS activity, and exerting anti-fibrotic, anti-hypertrophic effects at the myocardial level.10 NT-proBNP and BNP are the most widely used biomarkers in HF diagnosis and prognostication. In HF, natriuretic peptide levels are markedly elevated, both reflecting the severity of wall stress and attempting to counteract neurohormonal overactivation. Neprilysin is the primary enzyme responsible for degrading natriuretic peptides (as well as bradykinin and angiotensin II). Pharmacological inhibition of neprilysin, combined with RAAS blockade via the drug sacubitril/valsartan (an ARNI), amplifies natriuretic peptide effects and has become a central component of GDMT for HFrEF (discussed in CHF-02).10
Arginine vasopressin (AVP), released in HF through baroreceptor-mediated stimulation of the posterior pituitary, acts on V1a receptors (vasoconstriction) and V2 receptors (aquaporin-2-mediated free water retention) to cause hyponatremia and contribute to congestion.6 Endothelin-1 (ET-1), produced by vascular endothelium, is a potent vasoconstrictor and mitogen upregulated in advanced HF. While endothelin receptor antagonists are established in pulmonary arterial hypertension, they have not demonstrated benefit in systemic HFrEF and are not part of standard GDMT.
Cardiac remodeling refers to the changes in ventricular geometry, mass, and function that occur in response to myocardial injury and chronic neurohormonal activation. Remodeling is the structural substrate through which HF progresses, and its reversal, reverse remodeling, is one of the key mechanisms through which GDMT improves outcomes.11
At the cellular level, remodeling involves: (1) cardiomyocyte hypertrophy (eccentric in volume-overload states, concentric in pressure-overload states); (2) cardiomyocyte loss through apoptosis, necrosis, and autophagy; (3) myofibroblast activation with progressive interstitial and perivascular fibrosis; (4) fetal gene re-expression with re-activation of beta-myosin heavy chain (slower, less efficient isoform) and downregulation of SERCA2a (the sarcoplasmic reticulum calcium ATPase responsible for rapid calcium cycling); and (5) alterations in extracellular matrix composition and metalloproteinase activity.11 These molecular changes translate into reduced contractile efficiency, impaired calcium handling, prolonged relaxation times, and increased myocardial stiffness.
The primary geometric consequence of HFrEF remodeling is progressive LV dilation and a shift from the normal elliptical to a spherical ventricular shape. This geometric change increases wall stress (by the law of Laplace: wall stress is proportional to pressure × radius / 2 × wall thickness), which in turn increases myocardial oxygen demand and worsens subendocardial perfusion. Mitral valve leaflet tethering due to papillary muscle displacement causes functional mitral regurgitation, adding a further volume burden to the already failing ventricle.11 The result is a self-amplifying cycle in which adverse remodeling worsens hemodynamics, which amplifies neurohormonal activation, which drives further remodeling. Interrupting this cycle through GDMT is the mechanistic basis for improving survival in HFrEF.
A critical finding from HFrEF trials is that GDMT, particularly ACE inhibitors/ARBs, beta-blockers, and ARNIs, can partially reverse pathological remodeling: reducing LV end-diastolic volume, restoring more elliptical geometry, reducing functional mitral regurgitation, and in some patients improving LVEF substantially.11 This reversal of remodeling is associated with improved survival and symptom burden. In some patients, particularly those with non-ischemic dilated cardiomyopathy, LVEF may normalize ("recovered HF"), though GDMT continuation is generally recommended to prevent recurrence.
The therapeutic targets in HFrEF can be organized according to the hemodynamic and neurohormonal parameters they address. This framework clarifies why multiple drug classes are used simultaneously and why combination therapy is superior to any single agent.2
Elevated ventricular filling pressures (preload) drive the congestion that causes dyspnea, orthopnea, and peripheral edema. Preload reduction is achieved through: (1) diuretics: primarily loop diuretics (furosemide, torsemide, bumetanide), which increase sodium and water excretion by blocking the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle; and (2) aldosterone antagonists (spironolactone, eplerenone), which block the mineralocorticoid receptor, reducing aldosterone-driven sodium retention and potassium wasting. Venodilators, including nitrates, also reduce preload through venous smooth muscle relaxation.2 Preload reduction primarily addresses symptoms and prevents decompensation but, except for aldosterone antagonists, does not directly reduce neurohormonal activation or reverse remodeling.
Elevated systemic vascular resistance (afterload) impedes LV ejection, worsening stroke volume and increasing wall stress. Afterload reduction through RAAS blockade (ACEi, ARBs, ARNIs) improves forward cardiac output, reduces wall stress. When combined with the anti-fibrotic and anti-hypertrophic properties of Ang II blockade, RAAS blockade directly contributes to reverse remodeling.2 Hydralazine, a direct arterial vasodilator, reduces afterload through a RAAS-independent mechanism and forms part of the hydralazine/isosorbide dinitrate combination used in ACEi/ARB-intolerant patients (particularly those of self-identified Black race, in whom this combination has demonstrated mortality benefit).2
Neurohormonal blockade is the dominant mechanism through which GDMT improves survival in HFrEF. The four pillars of neurohormonal blockade are: (1) RAAS blockade: through ACEi, ARB, or ARNI (sacubitril/valsartan), amplifying natriuretic peptide effects while suppressing Ang II-mediated remodeling; (2) beta-blockade: through carvedilol, metoprolol succinate, or bisoprolol, attenuating catecholamine-mediated myocardial toxicity and promoting beta-1 receptor re-sensitization; (3) mineralocorticoid receptor antagonism: through spironolactone or eplerenone, blocking aldosterone-driven fibrosis and sodium retention; and (4) SGLT2 inhibition: through dapagliflozin or empagliflozin, the mechanism of which in HF extends well beyond glycosuria and includes reduction in ventricular preload/afterload, anti-inflammatory and anti-fibrotic effects, improved myocardial energetics, and possible direct cardioprotective actions.2 The combination of all four classes constitutes current four-pillar GDMT.
Inotropic agents increase myocardial contractility by increasing intracellular calcium availability (digoxin, dobutamine, milrinone) or reducing its degradation. While effective in symptom management and hemodynamic stabilization, positive inotropes carry risks, particularly proarrhythmia and increased myocardial oxygen demand, that limit their long-term use. They are reserved for acute decompensation with hemodynamic compromise, bridge therapy in advanced HF, and palliative care.2 Digoxin occupies a unique niche: it has modest positive inotropic effects, but its primary benefit in HF is through increased vagal tone and reduced sympathetic activation, modestly reducing hospitalizations without mortality benefit.
Beyond hemodynamic effects, several GDMT agents exert direct anti-remodeling actions: ACEi/ARBs reduce Ang II-driven myocyte hypertrophy and fibroblast activation; aldosterone antagonists block the pro-fibrotic effects of mineralocorticoid receptor activation; SGLT2 inhibitors may attenuate myocardial fibrosis through effects on NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation and cardiac autophagy.4 These mechanisms help explain why GDMT produces sustained mortality benefit that exceeds what hemodynamic improvement alone would predict.
The concept of "four-pillar GDMT" has emerged from the convergence of landmark trials demonstrating additive survival benefit from each drug class in HFrEF. The 2022 AHA/ACC/HFSA guidelines and the 2021 ESC guidelines both now recommend simultaneous or rapid-sequence initiation of all four pillars rather than sequential up-titration, recognizing that survival benefit accrues from each pillar independently and that deferring any class represents a lost opportunity.2·3 Pillar 1 (RAAS blockade): ACE inhibitor, ARB, or ARNI (sacubitril/valsartan). The ARNI is preferred over ACEi or ARB for most patients with HFrEF who can tolerate it, based on the PARADIGM-HF trial demonstrating superior mortality reduction. In patients who cannot tolerate an ARNI (due to cost, hypotension, or angioedema), an ACEi or ARB is appropriate.2 (CHF-02) Pillar 2 (Beta-blockade): Carvedilol, metoprolol succinate, or bisoprolol. Only these three agents have demonstrated mortality benefit in HFrEF and should be used exclusively; other beta-blockers are not interchangeable for this indication.2 (CHF-03) Pillar 3 (Mineralocorticoid receptor antagonist, MRA): Spironolactone or eplerenone. Indicated in HFrEF with LVEF ≤35% and New York Heart Association (NYHA) class II–IV symptoms, with adequate renal function and potassium levels. Eplerenone is preferred in post-MI HF and in patients who develop spironolactone-related endocrine side effects.2 (CHF-04) Pillar 4 (SGLT2 inhibitor): Dapagliflozin or empagliflozin. Both are now guideline-recommended for HFrEF regardless of diabetes status, with Class I recommendations in the 2022 AHA/ACC/HFSA guidelines. Both have also demonstrated benefit in HFpEF/HFmrEF.2 (CHF-05) Beyond these four pillars, vericiguat (soluble guanylate cyclase stimulator), ivabradine (If-channel inhibitor for elevated resting heart rate), and hydralazine/isosorbide dinitrate (for ACEi/ARB-intolerant patients, particularly those of Black race) represent adjunctive options in selected patients.2
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11
doi:10.15420/cfr.2016:25:2Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–e421
doi:10.1016/j.jacc.2021.12.012McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726
doi:10.1093/eurheartj/ehab368Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016;375(19):1868–1877
doi:10.1056/NEJMcp1511175Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261(6):884–888
doi:10.1001/jama.1989.03420060100040Bristow MR. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109(10):1176–1194
doi:10.1161/CIRCRESAHA.111.245092Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation. 1990;81(4):1161–1172
doi:10.1161/01.CIR.81.4.1161Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21
doi:10.1056/NEJMoa1009492Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–823
doi:10.1056/NEJM198409273111303McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004
doi:10.1056/NEJMoa1409077Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling — concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35(3):569–582
doi:10.1016/S0735-1097(99)00630-0